소마토스타틴 유사체 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Somatostatin Analogs Market Growth & Trends:

The global somatostatin analogs market size is anticipated to reach USD 11.1 billion by 2030 and expand at a CAGR of 13.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.

The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

Somatostatin Analogs Market Highlights

• By type, octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024.
• The pasireotide segment is expected to grow at the fastest CAGR over the forecast period.
• By application, the NET segment dominated the somatostatin analogs market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
• Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024.
• Hospitals dominated the market in 2024, and the clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period.
• North America dominated the global market owing to the presence of key players in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Somatostatin Analogs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Somatostatin Analogs Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Octreotide
  • 4.4.1. Octreotide Market, 2018 - 2030 (USD Million)
• 4.5. Lanreotide
  • 4.5.1. Lanreotide Market, 2018 - 2030 (USD Million)
• 4.6. Pasireotide
  • 4.6.1. Pasireotide Market, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 5. Somatostatin Analogs Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Acromegaly
  • 5.4.1. Somatostatin Analogs Market, in Acromegaly, 2018 - 2030 (USD Million)
• 5.5. NET
  • 5.5.1. Somatostatin Analogs Market, in NET, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Somatostatin Analogs Market, in Others, 2018 - 2030 (USD Million)

Chapter 6. Somatostatin Analogs Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals Segment Market, 2018 - 2030 (USD Million)
• 6.5. Clinics
  • 6.5.1. Clinics Segment Market, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 7. Somatostatin Analogs Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Denmark Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Sweden Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Norway Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.10. Russia
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Regulatory Framework
    • 7.5.10.3. Competitive Insights
    • 7.5.10.4. Russia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6.2. India
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. India Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Korea
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. South Korea Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Hong Kong
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. Hong Kong Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Singapore
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Singapore Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Japan
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Regulatory Framework
    • 7.6.8.3. Competitive Insights
    • 7.6.8.4. Japan Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.9. Thailand
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Regulatory Framework
    • 7.6.9.3. Competitive Insights
    • 7.6.9.4. Thailand Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. Kuwait
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. Kuwait Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. South Africa
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. South Africa Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. UAE
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. UAE Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Novo Nordisk A/S
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Type Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Pfizer Inc.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Type Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Eli Lilly and Company
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Type Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Medical Device Business Services, Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Type Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Johnson & Johnson Services, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Type Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Stryker
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Type Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Ultragenyx Pharmaceutical Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Type Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Alexion Pharmaceuticals, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Type Benchmarking
    • 8.5.8.4. Strategic Initiatives